ATE421526T1 - Prodrugs von exzitatorischen aminosäuren - Google Patents
Prodrugs von exzitatorischen aminosäurenInfo
- Publication number
- ATE421526T1 ATE421526T1 AT03757266T AT03757266T ATE421526T1 AT E421526 T1 ATE421526 T1 AT E421526T1 AT 03757266 T AT03757266 T AT 03757266T AT 03757266 T AT03757266 T AT 03757266T AT E421526 T1 ATE421526 T1 AT E421526T1
- Authority
- AT
- Austria
- Prior art keywords
- prodrugs
- amino acids
- excitatory amino
- excitatory
- acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02380120 | 2002-06-11 | ||
EP02380121 | 2002-06-11 | ||
US41593702P | 2002-10-03 | 2002-10-03 | |
US41593602P | 2002-10-03 | 2002-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE421526T1 true ATE421526T1 (de) | 2009-02-15 |
Family
ID=29740902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03757266T ATE421526T1 (de) | 2002-06-11 | 2003-06-06 | Prodrugs von exzitatorischen aminosäuren |
Country Status (30)
Country | Link |
---|---|
US (5) | US7371872B2 (de) |
EP (2) | EP1517915B1 (de) |
JP (2) | JP4342437B2 (de) |
KR (1) | KR20080058509A (de) |
AR (1) | AR040257A1 (de) |
AT (1) | ATE421526T1 (de) |
AU (1) | AU2003232146B2 (de) |
BR (1) | BR0311558A (de) |
CA (1) | CA2488167C (de) |
CO (1) | CO5631438A2 (de) |
CR (2) | CR7616A (de) |
CY (1) | CY1108976T1 (de) |
DE (1) | DE60325968D1 (de) |
DK (1) | DK1517915T3 (de) |
EA (2) | EA014979B1 (de) |
EC (1) | ECSP085481A (de) |
ES (1) | ES2319116T3 (de) |
HK (1) | HK1075259A1 (de) |
HR (2) | HRP20041179B1 (de) |
IL (2) | IL165100A0 (de) |
MX (1) | MXPA04012518A (de) |
MY (1) | MY146238A (de) |
NO (2) | NO331780B1 (de) |
NZ (3) | NZ556437A (de) |
PE (1) | PE20040555A1 (de) |
PL (1) | PL221489B1 (de) |
PT (1) | PT1517915E (de) |
SI (1) | SI1517915T1 (de) |
WO (1) | WO2003104217A2 (de) |
ZA (1) | ZA200409553B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ556437A (en) * | 2002-06-11 | 2008-11-28 | Lilly Co Eli | Prodrugs of excitatory amino acids |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
NZ584145A (en) | 2007-09-14 | 2012-03-30 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
MX2011005242A (es) | 2008-11-28 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. |
WO2010111080A2 (en) | 2009-03-27 | 2010-09-30 | Eli Lilly And Company | Optimized treatment of schizophrenia |
MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
CA2760259C (en) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
PL3795669T3 (pl) * | 2009-06-29 | 2024-03-18 | Inolex Investment Corporation | Nieropopochodne emulgatory kationowe będące estrami zobojętnionych aminokwasów oraz pokrewne kompozycje i sposoby |
AR079343A1 (es) | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
WO2012068041A1 (en) * | 2010-11-18 | 2012-05-24 | Eli Lilly And Company | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
AU2012271024B2 (en) | 2011-06-17 | 2015-07-09 | Eli Lilly And Company | Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mGlu2 receptor agonist |
AR089718A1 (es) * | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
EP2857385B1 (de) | 2012-06-01 | 2017-08-02 | Taisho Pharmaceutical Co., Ltd. | Prodrug aus fluorhaltiger aminosäure |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
WO2015110435A1 (en) * | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
ME03518B (de) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinationen mit positiven allosterischen modulatoren von metabotropem glutamatergen rezeptor vom subtyp 2 und deren verwendung |
CN108774274B (zh) * | 2015-03-06 | 2020-11-03 | 北京大学 | 唾液酸甲酯甲苷衍生物及其合成方法和应用 |
CA2991661A1 (en) | 2015-07-09 | 2017-01-12 | Mimetogen Pharmaceuticals, Inc. | Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US200488A (en) | 1878-02-19 | Improvement in temporary binders | ||
US1459765A (en) * | 1922-03-18 | 1923-06-26 | Wordsworth M Elliott | Interchangeable sign letters |
WO1993006127A1 (en) | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
DE69529209T2 (de) * | 1995-03-14 | 2003-11-13 | Brown & Sharpe Tesa S.A., Renens | Element mit einem geregelten Diodenlaser, und elektrooptische Vorrichtung unter Verwendung eines derartigen Elements |
ZA969486B (en) * | 1995-11-16 | 1998-05-12 | Lilly Co Eli | Excitatory amino acid derivatives. |
US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
EP1052246B1 (de) * | 1998-01-28 | 2003-04-02 | Taisho Pharmaceutical Co., Ltd | Fluorhaltige aminosäurederivate |
EP1110943B1 (de) | 1998-08-31 | 2004-06-16 | Taisho Pharmaceutical Co. Ltd. | 6-fluoro[3.1.0]hexan-derivate |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6313498B1 (en) * | 1999-05-27 | 2001-11-06 | Actrans System Inc. | Flash memory cell with thin floating gate with rounded side wall, and fabrication process |
AU2001267854B2 (en) * | 2000-06-28 | 2005-12-01 | Taisho Pharmaceutical Co., Ltd. | Novel dicarboxylic acid derivatives |
HUP0400620A3 (en) | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
US7038077B2 (en) * | 2001-01-11 | 2006-05-02 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
NZ533699A (en) | 2001-12-27 | 2006-05-26 | Taisho Pharmaceutical Co Ltd | 6-fluorobicyclo[3.1.0]hexane derivatives |
US20050192273A1 (en) * | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
AU2003218063A1 (en) * | 2002-04-03 | 2003-10-20 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
NZ556437A (en) | 2002-06-11 | 2008-11-28 | Lilly Co Eli | Prodrugs of excitatory amino acids |
-
2003
- 2003-06-06 NZ NZ556437A patent/NZ556437A/en not_active IP Right Cessation
- 2003-06-06 EP EP03757266A patent/EP1517915B1/de not_active Expired - Lifetime
- 2003-06-06 EA EA200801711A patent/EA014979B1/ru not_active IP Right Cessation
- 2003-06-06 NZ NZ536459A patent/NZ536459A/en not_active IP Right Cessation
- 2003-06-06 DK DK03757266T patent/DK1517915T3/da active
- 2003-06-06 AU AU2003232146A patent/AU2003232146B2/en not_active Expired
- 2003-06-06 EP EP07122014A patent/EP1897550A3/de not_active Withdrawn
- 2003-06-06 EA EA200500007A patent/EA011231B1/ru not_active IP Right Cessation
- 2003-06-06 US US10/516,559 patent/US7371872B2/en not_active Expired - Lifetime
- 2003-06-06 KR KR1020087013701A patent/KR20080058509A/ko not_active Application Discontinuation
- 2003-06-06 SI SI200331575T patent/SI1517915T1/sl unknown
- 2003-06-06 JP JP2004511287A patent/JP4342437B2/ja not_active Expired - Lifetime
- 2003-06-06 WO PCT/US2003/015405 patent/WO2003104217A2/en active Application Filing
- 2003-06-06 AT AT03757266T patent/ATE421526T1/de active
- 2003-06-06 NZ NZ564692A patent/NZ564692A/en not_active IP Right Cessation
- 2003-06-06 PL PL374381A patent/PL221489B1/pl unknown
- 2003-06-06 BR BRPI0311558-5A patent/BR0311558A/pt not_active Application Discontinuation
- 2003-06-06 ES ES03757266T patent/ES2319116T3/es not_active Expired - Lifetime
- 2003-06-06 MX MXPA04012518A patent/MXPA04012518A/es active IP Right Grant
- 2003-06-06 DE DE60325968T patent/DE60325968D1/de not_active Expired - Lifetime
- 2003-06-06 PT PT03757266T patent/PT1517915E/pt unknown
- 2003-06-06 CA CA2488167A patent/CA2488167C/en not_active Expired - Lifetime
- 2003-06-09 PE PE2003000574A patent/PE20040555A1/es not_active Application Discontinuation
- 2003-06-09 MY MYPI20032147A patent/MY146238A/en unknown
- 2003-06-10 AR ARP030102065A patent/AR040257A1/es active IP Right Grant
-
2004
- 2004-11-08 IL IL16510004A patent/IL165100A0/xx not_active IP Right Cessation
- 2004-11-25 ZA ZA2004/09553A patent/ZA200409553B/en unknown
- 2004-12-07 CO CO04122695A patent/CO5631438A2/es not_active Application Discontinuation
- 2004-12-09 CR CR7616A patent/CR7616A/es unknown
- 2004-12-10 HR HRP20041179AA patent/HRP20041179B1/hr not_active IP Right Cessation
-
2005
- 2005-01-10 NO NO20050122A patent/NO331780B1/no not_active IP Right Cessation
- 2005-08-31 HK HK05107648.6A patent/HK1075259A1/xx not_active IP Right Cessation
-
2008
- 2008-02-07 IL IL189355A patent/IL189355A/en not_active IP Right Cessation
- 2008-02-12 NO NO20080765A patent/NO20080765L/no not_active Application Discontinuation
- 2008-02-13 JP JP2008031490A patent/JP2008201779A/ja active Pending
- 2008-03-31 US US12/059,112 patent/US7671082B2/en not_active Expired - Lifetime
- 2008-04-03 EC EC2008005481A patent/ECSP085481A/es unknown
-
2009
- 2009-01-30 HR HR20090058A patent/HRP20090058A2/xx not_active Application Discontinuation
- 2009-04-07 CY CY20091100411T patent/CY1108976T1/el unknown
-
2010
- 2010-01-15 US US12/688,074 patent/US7964632B2/en not_active Expired - Lifetime
-
2011
- 2011-03-10 CR CR20110130A patent/CR20110130A/es not_active Application Discontinuation
- 2011-05-04 US US13/100,642 patent/US8153683B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 US US13/418,613 patent/US20120172422A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60325968D1 (de) | Prodrugs von exzitatorischen aminosäuren | |
NO20054958D0 (no) | Substitulerte aminokarboksylsyrer | |
DK1543038T4 (da) | Proteinoprensning | |
DE60235619D1 (de) | Kondensierte bizyklische oder trizyklische aminosäuren | |
IS7951A (is) | Amínósýrur sem eru næmar fyrir a2ð-prótíninu | |
DK1478328T3 (da) | Bioaktive keratinpeptider | |
NO20033078L (no) | Hydrolysat av fiskeprotein | |
NO20052807D0 (no) | Fremgangsmate for fremstilling av aminosyrer | |
DE60327407D1 (de) | Immunmodulierende peptide | |
DE60217089D1 (de) | Lipidsenkende biphenylcarbonsäureamide | |
IS8338A (is) | Framleiðsla sómatóstatínpeptíða | |
DE602004026242D1 (de) | Derivate von alkalischen Aminosäuren als Geliermitteln | |
DE602004023417D1 (de) | Oxazolderivate von tetracyclinen | |
ATE356111T1 (de) | Prodrugs von exzitatorischen aminosäuren | |
DE602004026773D1 (de) | Verfahrensherstellung von ethern | |
AU2002353845A1 (en) | Prodrugs of excitatory amino acids | |
NO20053512D0 (no) | IL-8-liknende proteiner | |
TWI315666B (en) | Prodrugs of excitatory amino acids | |
NO20054532D0 (no) | Fremgangsmater for a forhindre glukonoylering av proteiner | |
NO20050436D0 (no) | Beta-lagnedbrytende peptider | |
DE50205590D1 (de) | Ummantelung von leiterbahnen | |
AU2003242924A1 (en) | Prodrugs of excitatory amino acids | |
AU2002361611A1 (en) | Prodrugs of excitatory amino acids | |
DE602004030633D1 (de) | Reinigung von Amidderivaten | |
NO20052608D0 (no) | Midkinlignende protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1517915 Country of ref document: EP |